Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1985 2
1986 1
1988 3
1989 4
1990 8
1991 2
1992 10
1993 6
1994 13
1995 20
1996 12
1997 22
1998 35
1999 39
2000 38
2001 35
2002 54
2003 68
2004 73
2005 105
2006 132
2007 123
2008 194
2009 220
2010 293
2011 365
2012 435
2013 534
2014 606
2015 743
2016 821
2017 898
2018 1063
2019 1339
2020 1700
2021 1877
2022 1351
Text availability
Article attribute
Article type
Publication date

Search Results

11,807 results
Results by year
Filters applied: . Clear all
Page 1
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Barr PM, et al. Among authors: zhou c. Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434. Blood Adv. 2022. PMID: 35377947 Free PMC article. Clinical Trial.
CCR5 closes the temporal window for memory linking.
Shen Y, Zhou M, Cai D, Filho DA, Fernandes G, Cai Y, de Sousa AF, Tian M, Kim N, Lee J, Necula D, Zhou C, Li S, Salinas S, Liu A, Kang X, Kamata M, Lavi A, Huang S, Silva T, Do Heo W, Silva AJ. Shen Y, et al. Among authors: zhou c. Nature. 2022 Jun;606(7912):146-152. doi: 10.1038/s41586-022-04783-1. Epub 2022 May 25. Nature. 2022. PMID: 35614219
STING controls energy stress-induced autophagy and energy metabolism via STX17.
Rong Y, Zhang S, Nandi N, Wu Z, Li L, Liu Y, Wei Y, Zhao Y, Yuan W, Zhou C, Xiao G, Levine B, Yan N, Mou S, Deng L, Tang Z, Liu X, Kramer H, Zhong Q. Rong Y, et al. Among authors: zhou c. J Cell Biol. 2022 Jul 4;221(7):e202202060. doi: 10.1083/jcb.202202060. Epub 2022 May 5. J Cell Biol. 2022. PMID: 35510944
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: zhou c. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Martin T, et al. Among authors: zhou c. J Clin Oncol. 2022 Jun 4:JCO2200842. doi: 10.1200/JCO.22.00842. Online ahead of print. J Clin Oncol. 2022. PMID: 35658469
CO2-elevated cell-free protein synthesis.
Lin X, Zhou C, Wang T, Huang X, Chen J, Li Z, Zhang J, Lu Y. Lin X, et al. Among authors: zhou c. Synth Syst Biotechnol. 2022 May 20;7(3):911-917. doi: 10.1016/j.synbio.2022.05.002. eCollection 2022 Sep. Synth Syst Biotechnol. 2022. PMID: 35664930 Free PMC article.
The fate of autophagosomal membrane components.
Wu Z, Zhou C, Que H, Wang Y, Rong Y. Wu Z, et al. Among authors: zhou c. Autophagy. 2022 Jun 2:1-2. doi: 10.1080/15548627.2022.2083807. Online ahead of print. Autophagy. 2022. PMID: 35635187
11,807 results
You have reached the last available page of results. Please see the User Guide for more information.